Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.71 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.71 |
| ▸ | TNF | P01375 | 2/20 | 0.71 |
| ▸ | IL1B | P01584 | 2/20 | 0.71 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311585 | 1.00 | CRBN (0.71) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL4389404 | 1.00 | CRBN (0.71) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL26051925 | 0.91 | CRBN (0.81) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL563317 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL369172 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930059 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL931134 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL19250920 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL29382107 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298882-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2009-12-03 | — | — | US | claimed |
| WO-2009139880-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090298882-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| WO-2009139880-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298882-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | TPMT, CYP3A7, UGT2B7 | CRBN 4405/4885DDB1 1975/4885IKZF3 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.